| Developing irreversible inhibitors of the protein kinase cysteinome Q Liu, Y Sabnis, Z Zhao, T Zhang, SJ Buhrlage, LH Jones, NS Gray Chemistry & biology 20 (2), 146-159, 2013 | 705 | 2013 |
| Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? Z Zhao, H Wu, L Wang, Y Liu, S Knapp, Q Liu, NS Gray ACS chemical biology 9 (6), 1230-1241, 2014 | 405 | 2014 |
| Progress with covalent small-molecule kinase inhibitors Z Zhao, PE Bourne Drug Discovery Today, 2018 | 191 | 2018 |
| Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor HG Kim, L Tan, EL Weisberg, F Liu, P Canning, HG Choi, SA Ezell, H Wu, ... ACS chemical biology 8 (10), 2145-2150, 2013 | 153 | 2013 |
| Brain penetrant LRRK2 inhibitor HG Choi, J Zhang, X Deng, JM Hatcher, MP Patricelli, Z Zhao, DR Alessi, ... ACS medicinal chemistry letters 3 (8), 658-662, 2012 | 133 | 2012 |
| Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics Q Liu, S Kirubakaran, W Hur, M Niepel, K Westover, CC Thoreen, J Wang, ... Journal of Biological Chemistry 287 (13), 9742-9752, 2012 | 129 | 2012 |
| Determining cysteines available for covalent inhibition across the human kinome Z Zhao, Q Liu, S Bliven, L Xie, PE Bourne Journal of Medicinal Chemistry 60 (7), 2879–2889, 2017 | 120 | 2017 |
| Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and … E Weisberg, Q Liu, E Nelson, AL Kung, AL Christie, R Bronson, M Sattler, ... Leukemia 26 (10), 2233-2244, 2012 | 88 | 2012 |
| Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma H Wu, W Wang, F Liu, EL Weisberg, B Tian, Y Chen, B Li, A Wang, ... ACS chemical biology 9 (5), 1086-1091, 2014 | 76 | 2014 |
| Crystal Structure of the GRAS Domain of SCARECROW-LIKE7 in Oryza sativa S Li, Y Zhao, Z Zhao, X Wu, L Sun, Q Liu, Y Wu The Plant Cell 28 (5), 1025-1034, 2016 | 62 | 2016 |
| Drug repurposing to target Ebola virus replication and virulence using structural systems pharmacology Z Zhao, C Martin, R Fan, PE Bourne, L Xie BMC bioinformatics 17, 1-12, 2016 | 51 | 2016 |
| Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia H Wu, C Hu, A Wang, EL Weisberg, Y Chen, CH Yun, W Wang, Y Liu, ... Leukemia 30 (1), 173-181, 2016 | 50 | 2016 |
| Discovery of a selective irreversible BMX inhibitor for prostate cancer F Liu, X Zhang, E Weisberg, S Chen, W Hur, H Wu, Z Zhao, W Wang, ... ACS Chemical Biology 8 (7), 1423-1428, 2013 | 50 | 2013 |
| Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome Z Zhao, L Xie, PE Bourne PLoS One 12 (6), e0179936, 2017 | 47 | 2017 |
| Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation A Wang, XE Yan, H Wu, W Wang, C Hu, C Chen, Z Zhao, P Zhao, X Li, ... Oncotarget 7 (43), 69760, 2016 | 42 | 2016 |
| Delineation of polypharmacology across the human structural kinome using a functional site interaction fingerprint approach Z Zhao, L Xie, L Xie, PE Bourne Journal of medicinal chemistry 59 (9), 4326-4341, 2016 | 41 | 2016 |
| Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells H Wu, A Wang, W Zhang, B Wang, C Chen, W Wang, C Hu, Z Ye, Z Zhao, ... Oncotarget 6 (31), 31313, 2015 | 39 | 2015 |
| Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML H Wu, C Hu, A Wang, EL Weisberg, W Wang, C Chen, Z Zhao, K Yu, J Liu, ... Leukemia 30 (3), 754-757, 2016 | 38 | 2016 |
| Structural Insights into Characterizing Binding Sites in Epidermal Growth Factor Receptor Kinase Mutants Z Zhao, L Xie, PE Bourne Journal of chemical information and modeling 59 (1), 453-462, 2019 | 32 | 2019 |
| Structural insights into the characterization of binding sites in EGFR kinase mutants Z Zhao, L Xie, PE Bourne Abstract of Intelligent Systems for Molecular Biology 2018 502, 2018 | 32* | 2018 |
